Sleep and Circadian Research Compounds
This page indexes catalogue compounds that appear in the sleep, circadian and stress-response research literature. It describes mechanism and evidence stage only, and is not guidance for use.
Compounds in This Area
- DSIP (delta sleep-inducing peptide, also called emideltide) — a nonapeptide first isolated from rabbit cerebral venous blood in the 1970s and characterised largely in animal electroencephalography models. Controlled human data is very limited. DSIP was one of the substances examined by the FDA Pharmacy Compounding Advisory Committee on the second day of its July 2026 meeting; that review concerns compounding eligibility and does not confer approved status.
- GABA — the principal inhibitory neurotransmitter in the mammalian central nervous system. Research interest in orally administered GABA centres substantially on whether, and to what degree, it crosses the blood–brain barrier, which remains contested in the literature.
- NAD⁺ — included in this area because NAD metabolism shows circadian oscillation via NAMPT, linking redox state to the molecular clock rather than to sleep behaviour directly. Background: NAD+ research.
Evidence Stage
The sleep and circadian peptide literature is thinner than the metabolic literature and rests more heavily on animal models and small, older human studies. Where a compound here has no controlled human data, that is stated in its entry in the Research Library. Regulatory status for this group is discussed in what determines regulatory status.
Research use only. All compounds referenced on this page are supplied for laboratory research use only. They are not drugs, foods or cosmetics, and are not for human or veterinary use. Nothing on this page is a therapeutic claim, and no diagnosis, treatment, cure or prevention of any condition is stated or implied.